首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >p38y and p385 kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation
【24h】

p38y and p385 kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation

机译:p38y和p385激酶通过控制ERK1 / 2蛋白激酶途径激活来调节Toll样受体4(TLR4)诱导的细胞因子产生

获取原文
获取原文并翻译 | 示例
       

摘要

On the basis mainly of pharmacological experiments, the p38α MAP kinase isoform has been established as an important regulator of immune and inflammatory responses. However, the role of the related p38γ and p388 kinases has remained unclear. Here, we show that deletion of p38γ and p38S impaired the innate immune response to lipopolysaccharide (LPS), a Toll-like receptor 4 (TLR4) ligand, by blocking the extracellular signal-regulated kinase 1/2 (ERK1/2) activation in macrophages and dendritic cells. p38γ and p388 were necessary to maintain steady-state levels of tumor progression locus 2 (TPL2), the MKK kinase that mediates ERK1/2 activation after TLR4 stimulation. TNFα, IL-1β, and IL-10 production were reduced in LPS-stimulated macrophages from p38γ/8-null mice, whereas IL-12 and IFNβ production increased, in accordance with the known effects of TPL2/ERK1/2 signaling on the induction of these cytokines. Furthermore, p38y/8-deficient mice were less sensitive than controls to LPS-induced septic shock, showing lower TNFα and IL-1β levels after challenge. Together, our results establish p38γ and p38δ as key components in innate immune responses.
机译:p38αMAP激酶同工型主要根据药理实验建立,是免疫和炎症反应的重要调节剂。然而,相关的p38γ和p388激酶的作用仍不清楚。在这里,我们显示p38γ和p38S的缺失通过阻断细胞外信号调节激酶1/2(ERK1 / 2)的激活而损害了对脂多糖(LPS)(一种Toll样受体4(TLR4)配体)的先天免疫应答。巨噬细胞和树突状细胞。 p38γ和p388是维持肿瘤进展基因2(TPL2)稳态水平所必需的,TPL2是MKK激酶,在TLR4刺激后介导ERK1 / 2激活。根据TPL2 / ERK1 / 2信号转导对p38γ/ 8-null小鼠的LPS刺激的巨噬细胞,TNFα,IL-1β和IL-10的产生减少,而IL-12和IFNβ的产生增加。这些细胞因子的诱导。此外,p38y / 8缺陷小鼠对LPS诱导的败血性休克的敏感性比对照组低,攻击后显示较低的TNFα和IL-1β水平。总之,我们的结果将p38γ和p38δ确定为先天免疫应答的关键成分。

著录项

  • 来源
  • 作者单位

    Department of Immunology and Oncology, Centra Nacional de Biotecnologia/Consejo Superior de Investigaciones Cientificas (CNB/CSIC), 28049-Madrid,Spain;

    Department of Immunology and Oncology, Centra Nacional de Biotecnologia/Consejo Superior de Investigaciones Cientificas (CNB/CSIC), 28049-Madrid,Spain;

    Division of Immune Cell Biology, National Institute for Medical Research, London NW7 1AA, United Kingdom;

    Department of Immunology and Oncology, Centra Nacional de Biotecnologia/Consejo Superior de Investigaciones Cientificas (CNB/CSIC), 28049-Madrid,Spain;

    Medical Research Council Protein Phosphorylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;

    Division of Immune Cell Biology, National Institute for Medical Research, London NW7 1AA, United Kingdom;

    Department of Immunology and Oncology, Centra Nacional de Biotecnologia/Consejo Superior de Investigaciones Cientificas (CNB/CSIC), 28049-Madrid,Spain;

    Department of Immunology and Oncology, Centra Nacional de Biotecnologia/Consejo Superior de Investigaciones Cientificas (CNB/CSIC), 28049-Madrid,Spain;

    Medical Research Council Protein Phosphorylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;

    Division of Immune Cell Biology, National Institute for Medical Research, London NW7 1AA, United Kingdom;

    Department of Immunology and Oncology, Centra Nacional de Biotecnologia/Consejo Superior de Investigaciones Cientificas (CNB/CSIC), 28049-Madrid,Spain;

    Department of Immunology and Oncology, Centra Nacional de Biotecnologia/Consejo Superior de Investigaciones Cientificas (CNB/CSIC), 28049-Madrid,Spain;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 00:40:26

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号